Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AJA030 placebo-controlled randomized trial in SCA6 spinocerebellar degeneration
jRCT2031200135Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in spinocerebellar ataxia type 6 (SCA6) and spinocerebellar ataxia (SCA) comparing AJA030 with Placebo (2 arms). Primary endpoint: Change from baseline in SARA total score at Week 48. Started Oct 2020; status: completed.
02
Drugs
acetazolamide
03
Conditions
spinocerebellar ataxia type 6 (SCA6)spinocerebellar ataxia (SCA)
Beyond the preview
Go deeper on jRCT2031200135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200135.